' Summary: The new photometric assay described by Fickenscher et al. (Thromb. Haemostas. 65 (1991) 535-540) j for the determination of factor XIII facilitates the diagnosis of factor XIII deficiency. In spite of easy handling, this | test should be used critically. Patients with hyperfibrinogenaemia showed factor XIII activities of less than 20%, i whereas with an optimized assay we found normal factor XIII values. Also, the use of a fixed period of incubation for the analysis is questionable, because the period of constant reaction rate occurs earlier and is shorter with high factor XIII activities and later and longer with low factor XIII activities. A linear relation between factor XIII activity and signal only exists up to 80% of activity.
Introduction
turbidity of the reaction mixture results in falsely low r, ,.
t, r. t j 4 **· r i*· factor XIII activities. These methods Start with the preEarher methods for the determination of coagulation . . . bentomte as a P«*ipitatmg agent. As factor XIII many processing Steps, often with a pretreatment of the is bound to fibrinogen, and the thrombin-mediated actisample (l -4). Continuous photometric tests for the devat i°n of factor xm is enhanced in-the presence of fitermination of factor XIII in pJasma have already been brinogen, the precipitation of this protein can lead to described. In these assays, the clotting of the fibrin, decreased factor XIII values (5) (6) (7) (8) (9) (10) . A new photometric formed by proteolysis of fibrinogen in the sample by test for the determination of factor XIII activity was thrombin, has to be inhibited. Otherwise, .the increasing therefore recently described, in which fibrinogen is not precipitated, but a fibrin aggregation inhibitor (gly-proarg-pro-ala-amide) is added to the System (11).
We have analysed the performance of this assay. The test was optimized to analyse samples from patients with hyperfibrinogenaemia and factor XIII activities of more than 80%.
io-3 ΔΑ/min b = to refer to μraol = average absorbance change (decrease) per rhinute = catalytic concentration
The average frorn at least 4 absorbance differences and the factor 1746 were used to calculate factor XIII activity in U/l (37 °C). Factor XIII activity (%) was estimated by using a linear Standard plasma calibration curve (for more details see under results).
Materials and Methods

Plasma samples
Blood specimens were obtained by venipuncture in 0.129 mol/l sodium citrate solution pH 6.05 (l part of sodium citrate and 9 parts of blood). After centrifugation for 15 minutes at 2000g and room temperature, citrate plasma was separated. Samples were stored at -20 °C for not longer than 4 weeks.
Reagents
Berichrom Factor XIII assay (lot: 24710; Behringwerke); Bovine fibrinogen FXIII-free (lot: 43; Behringwerke); pure FXIII from human plasma (lot: 089791; Calbiochem); fibrin aggregation inhibitor gly-pro-arg-pro-ala-amide, 86% (lot: 64HSO4; Behringwerke); CTS Standard plasma (lot: 511513A; Behringwerke); CTS control plasma N (lot: 511612A; Behringwerke); CTS control plasma P (lot: 512612A; Behringwerke); sodium Chloride solution, 154 mmol/1 in double distilled water.
Instrumentation
Spectrophotometer Lambda 5 (Perkin-Elmer) fully mechanised with cuvette exchange Station which can be temperature controlled at 37 ± 0.2 °C (water bath) and plotter.
Statistical analysis
The Kolmogoroff-Smirnow-fittmg test and Lilliefors limits were used to examine whether the reference values are normally distributed (12) (13) (14) .
Methods
Assay according to Fickenscher
The reaction mixture was reconstituted in double distilled water according to the manufacturer's instructions and incubated in l mlaliquots in reaction tubes at 37 °C (water bath). After addition of 100 μΐ sample and mixing in the reaction tube the measurement was carried out in semimicro cuvettes prewarmed to 37 °C. Absorbance differences per minute (ΔΛ/min) were monitored continuously over a period of up to 40 minutes. In this time the period of constant reaction rate was determined in which the change of absorbance per minute did not differ by more than 0.005/min. The catalytic concentration was calculated according to LamberuBeerBouguer's law (15) 
Optimized assay
The NAD reagent was dissolved in a solution containing l g/l fibrin aggregation inhibitor in distilled water. Activator reagent (containing 5 mg liophilised fibrin aggregation inhibitor) was reconstituted with 5 ml of the dissolved NADH reagent to give 2 g/l fibrin aggf egation inhibitor. The detection reagent was rec nstituted with double distilled water and mixed with an equal volume of the rer constituted activator reagent tp give the reaction mixture containing l g/l fibrin aggregation inhibitor. Determination of factor ΧΙΠ activity was perforrned s described above. For the reduced sample volume of 50 μΐ the catalytic concentration is obtained s follows:
,-3 630-10^3-0.01 0.05 · 10^: = M/min · 3333
Results
As described in the literature (10, 11) , during the first 3 minutes after the Start of the reaction the registration curve shows a decrease of absorbance due to the conversion of endogenous ammoriia ( fig. 1 ). In plasma samples with normal fibrinogen concentrations, a continuous decrease of the absorbance was observed. The lower the factor XIII activity, the longer the linear period of the reaction (up to 15 to 20 minutes); but with low factor ΧΠί activity, the linear reaction period Starts later ( fig.  2 ). Samples from patients with hyperfibrinogenaemia form a clot in the cuvette during the measurement, which makes the Interpretation of the results impossible ( fig. 3 ). The assay was therefore modified by raising the concentration of the fibrin aggregation inhibitor from 0.5 g/l to 1.0 g/l. This had no adverse effect in the determination of a pool plasma ftoin 10 persons (flg. 4),· whereas in a patient with hyperfibrinogenaernia the detection of factor XIII activity was improved. After 11 minutes, clot formation simulates an increase of absorbance (flg. 5). With 50% predilution of the patient sample (in 154 mmol/1 aqueous NaCl solution) the measured factor XIII activity increased frorn 97 U/l in the non-optimized to 133 U/l in the aptimized assay (flg. 3 and 5).
Examination of the dilution limit with the unmodified reagent resulted in a linear measurement r nge up to 80% or 82 U/l (37 °C). The modified Version of the test showed an equivalent value. Using 50 μΐ sample instead of 100 .μΐ expands the r nge of linearity to 140%, corresponding to 128 U/l (37 °C) ( fig. 6 ). The calculation factor changes to 3333.
In patients with hyperfibrinogenaernia, all samples showed lower activities of factor XIII in the conventional assay Using a 50% reduced sample volume, 50% (3/6) of the patients seemed to have a decreased factor XIII activity of less than 20%. Determination of factor XIII activity with the twofold optimized assay showed normal results in all patients (tab. 1).
The twofold optimized test variant was used to determine the precision data and to determine the reference interval: 50 μΐ sample added to 1000 μΐ detection re-2.0 r Tab. l Factor XIII activities in patients with hyperfibrinogenaemia, using the unmodified assay according to Fickenscher with normal and reduced sample volume, and the optimized assay. agent containing 1.0 g/l fibrin aggregation inhibitor. The appropriate period for calculating factor XIII activity from the ΔΛ/min was determined (usually between 10 and 40 minutes) for each assay.
The precision was 2.3% in series and 2.8% from day to day, for a control plasma with 81 U/l (37 °C). The corresponding values for a control plasma with 35 U/l (37 °C) were 4.9% and 5.8%, respectively. With 100 apparently healthy persons, employees and students of the university, between 19 and 44 years of age, the reference interval ranged from 66 to 142 U/l (37 °C) or from 73 to 155%, and showed a normal distribution of the values ( fig. 7 ).
Discussion
The continuous UV test for the determination of factor XIII activity described by Fickenscher et al. (11) represents a significant advance compared with earlier methods. The results shown in, this paper demonstrate that the method must be applied critically.
Using a fixed period of incubatiqn (5 to 10 minutes (11, 16, 17) ) does not lead to correct values. The period of constant reaction rate varies with different factor XIII activities from 4 to 20 minutes. A variable assessment of each single reaction course has t be iade (flg. 2).
Furthermore it is shown that the added amount of the fibrin aggregation inhibitor is not s fficient to avoid clot formation in reaction mixtures from patients with hyperfibrinogenaemia. Even a reduced sample volume of 50 μΐ, s reeommended by the manufacturer (reducing the fibrinogen concentrations to the upper limit of the reference interval) simulates a factor XIII deficiency of 15 U/l or less in 50% (3/6) of the patients (tab. 1). The authors (11) describe a recovery of 96% factor XIII with a fibrinogen concentration of 10.5 g/l. A possible explanation of this findirig is that they added artificially purified fibrinogen to pooled plasma and did not analyse samples from patients with hyperfibrinogenaemia. In our study, the results are 2 to 3-fold higher, the time required to attain a constant reaction rate is longer, and the reaction curve was smoother using purified factor XIII and purified fibrinogen than in a matrix of human plasma ( fig. 2) enzyme activity show a negligible decrease ( fig. 6 ). This is, however, compensated by determining the reference interval under the same conditions. On the other band, even in samples from patients with high fibrinogen concentrations, the recorded factor XIII activities are higher than those found with the unmodified test (tab. 1).
Using the original method, we could not confirm the linearity limit of 150% factor XIII activity described in the literature. We found a value of 80%, corresponding to 82 U/l. A possible explanation is that the other authors analysed the change of absorbance between 5 and 10 minutes, while in the present study the period ofconstant reaction rate up to at least 20 minutes was used (11, 16, 17) . For low factor XIII activities the 5 to 10 minute interval yields lower results, because the reaction rate is still rising and the constant period is later.
, · Based on the data of this study a final modification of the method was developed:
-The sample volume in the test is reduced from 100 to 50 .
-The concentration of the fibrin aggregation inhibitor in the detection reagent is raised to 1.0 g/l.
This allows the analysis of samples with factor XIII activities of more than 140% or 128 U/l (37 °C) and with elevated fibrinogen concentrations with a reduced sensitivity. The reference interval was also slightly higher (73-155%) than in other studies (70-140% (11), 67-147% (16), 60-133% (17)). An assay with an increased concentration of fibrin aggregation inhibitor will in ftiture be available from the manufacturer.
